Abstract 1092P
Background
Previous studies demonstrate limited efficacy of immune checkpoint inhibitors in patients with irresectable acral melanoma (AM) compared to cutaneous melanoma (CM) in other locations. However, little is known about the outcomes of adjuvant therapy for resectable stage III-IV AM. This study aims to compare clinical outcomes after treatment with adjuvant anti-PD-1 in resectable stage III-IV AM and compare them to CM.
Methods
All patients with stage III-IV AM and CM who received adjuvant anti-PD-1 after complete resection between 2017 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We described baseline characteristics and analyzed the recurrence-free survival (RFS). A multivariable Cox regression analysis was performed to account for potential confounders age, performance status (ECOG), AJCC 8th edition disease stage, mutation status. Type of recurrence (locoregional or distant metastases) and toxicity rates will be presented at the conference.
Results
In total, 1977 patients (86 AM and 1891 CM) were included. At baseline, KIT mutations were more common in AM patients. In addition, AM patients more often had higher AJCC 8 disease stages. No other significantly different baseline characteristics were identified. Median follow-up was 16.4 months. The median RFS was 14.8 months (95%CI: 11.5-29.7) for the AM cohort and 37.4 months (95%CI: 32.1 - NR) for the CM cohort (p=.002)). After correcting for potential confounders, AM remained associated with higher risk of recurrence than CM (HRadj 1.55; 95%CI: 1.09-2.19; p=.014). Table: 1092P
Baseline characteristics and median RFS stratified by melanoma type.
AM (n=86) | CM (n=1891) | P-value | ||
Median age (IQR) | 65 [54, 72] | 64 [54, 73] | .984 | |
Gender (n (%) female) | 45 (52.3) | 793 (41.9) | .160 | |
AJCC8 stage (n (%)) | IIIA | 5 (5.7) | 130 (6.9) | .001 |
IIIB | 17 (19.5) | 599 (31.7) | ||
IIIC | 58 (66.7) | 713 (37.7) | ||
IIID | 2 (2.3) | 37 (2.0) | ||
IV | 2 (2.3) | 170 (9.0) | ||
Unknown | 3 (3.4) | 241 (12.8) | ||
Mutation (n (%)) | BRAF | 23 (26.7) | 804 (42.5) | .001 |
NRAS | 9 (10.5) | 441 (23.3) | ||
KIT | 7 (8.1) | 12 (0.6) | ||
Median RFS (months; 95% CI) | 14.8 (11.5-29.3) | 37.4 (32.1-NA) | .002 |
Conclusions
This study suggests that AM patients treated with adjuvant anti-PD-1 have shorter RFS than CM patients receiving the same treatment. Longer follow-up is needed to investigate overall survival and distant-metastasis-free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Achilles Therapeutics, Ipsen, Merck Sharp & Dohme, Merck Serono, Pfizer, Molecular Partners, Novartis, Roche, Sanofi, Third Rock Venture, Iovance Biotherapeutics; Financial Interests, Institutional, Advisory Board, SAB member: BioNTech, Immunocore, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board, SAB member: Neogene Therapeutics, Scenic; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, BioNTech US, Merck Sharp & Dohme, Amgen, Novartis, Asher Bio; Non-Financial Interests, Member: ASCO, AACR, SITC; Other, Other, Editorial Board ESMO Open: ESMO; Other, Other, Editor-in-Chief IOTECH: ESMO; Other, Editorial Board: Kidney Cancer. C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre; Financial Interests, Personal, Advisory Board: Third Rock Ventures; Financial Interests, Personal, Stocks/Shares: Immagene; Financial Interests, Personal, Stocks/Shares, intention to develop IFN signature algorithm: NewCo, no name yet; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, NanoString, 4SC; Other, pending patent: WO 2021/177822 A1. M.J.B. Aarts: Financial Interests, Advisory Board: Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer; Financial Interests, Institutional, Research Grant: Merck-Pfizer. J.W. de Groot: Financial Interests, Advisory Role: BMS, Pierre Fabre, Servier, MSD, Novartis. G.A.P. Hospers: Financial Interests, Advisory Role: Amgen, BMS, Roche, MSD, Pfizer, Novartis, Pierre Fabre; Financial Interests, Institutional, Research Grant: BMS, Seerave. E. Kapiteijn: Financial Interests, Institutional, Advisory Board: BMS, Novartis, Pierre Fabre, Merck, Delcath, Bayer, Lilly; Financial Interests, Institutional, Coordinating PI: BMS, Pierre Fabre, Delcath. R.S. van Rijn: Financial Interests, Advisory Board: Pfizer; Financial Interests, Other, expert meeting fee: Roche. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Role: BMS, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, Merck; Financial Interests, Institutional, Advisory Board: MSD. M.J. Boers-Sonderen: Financial Interests, Advisory Role: Pierre Fabre, MSD, Novartis. F. Van Den Eertwegh: Financial Interests, Institutional, Research Grant, Grant for national trial: Roche; Financial Interests, Institutional, Research Grant, Grant for research project: BMS; Financial Interests, Institutional, Research Grant, Research grant for trial: Sanofi, Idera; Financial Interests, Institutional, Research Grant, Grant for trial: Teva; Non-Financial Interests, Advisory Role: BMS, Novartis, Pierre Fabre, MSD, Pfizer, Amgen, Ipsen, Merck. K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.
Resources from the same session
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12